{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T07:43:19Z","timestamp":1780386199539,"version":"3.54.1"},"reference-count":43,"publisher":"Informa UK Limited","issue":"9","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2020,9,1]]},"DOI":"10.1080\/13696998.2020.1776719","type":"journal-article","created":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T19:04:15Z","timestamp":1591038255000},"page":"978-984","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":11,"title":["Estimating health state utilities associated with a rare disease: familial chylomicronemia syndrome (FCS)"],"prefix":"10.1080","volume":"23","author":[{"given":"Louis S.","family":"Matza","sequence":"first","affiliation":[{"name":"Patient-Centered Research, Evidera, Bethesda, MD, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn A.","family":"Phillips","sequence":"additional","affiliation":[{"name":"Value & Evidence Generation, Rhythm Pharmaceuticals, Boston, MA, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy A.","family":"Howell","sequence":"additional","affiliation":[{"name":"Patient-Centered Research, Evidera, Bethesda, MD, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Ciffone","sequence":"additional","affiliation":[{"name":"Arizona Center for Advanced Lipidology, Tucson, AZ, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahid","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,7,1]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02617.x"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2018.01.007"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2019.01.005"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-018-0930-3"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2018.03.004"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2018.01.008"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60872-7"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.430"},{"key":"CIT0009","unstructured":"Food and Drug Administration (FDA). Rare diseases: common issues in drug development guidance for industry. January 2019 [cited 2019 Oct 1]. Available from: https:\/\/www.fda.gov\/media\/119757\/download"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2018.02.008"},{"key":"CIT0011","unstructured":"Canadian Agency for Drugs and Technologies in Health (CADTH). Guidelines for the economic evaluation of health technologies: Canada. 4th ed. Mar 2017. Ottawa: CADTH; p. 71."},{"key":"CIT0012","unstructured":"Haute Autorite de Sante (HAS). A methodological guide: choices in methods for economic evaluation. La Plaine Saint-Denis, France: Department of Economics and Public Health Assessment; October 2012. p. 55."},{"key":"CIT0013","volume-title":"EQ-5D concepts and methods: a developmental history","author":"Kind P","year":"2010"},{"key":"CIT0014","unstructured":"National Institute for Health and Care Excellence (NICE). Process and methods guides: Guide to the methods of technology appraisal 2013 (PMG9). London, UK; April 2013. p. 93."},{"key":"CIT0015","unstructured":"Pharmaceutical Benefits Advisory Committee (PBAC). Guidelines for preparing a submission to the Pharmaceutical Benefits Advisory Committee, in Australian Government, Department of Health. Canberra, Australia; September 2016. p. 216."},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2017.05.015"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-018-0810-x"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1080\/14779072.2017.1311786"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400284"},{"key":"CIT0020","volume-title":"Familial lipoprotein lipase deficiency. GeneReviews","author":"Burnett JR","year":"1993"},{"issue":"2","key":"CIT0021","first-page":"105","volume":"98","author":"Pouwels ED","year":"2008","journal-title":"S Afr Med J"},{"key":"CIT0022","unstructured":"Rare disease report, familial chylomicronemia syndrome - proper management of FCS is critical. Silver Spring, MD: FDA; 2017 [cited 2018 May 30]. Available from: http:\/\/fcs.raredr.com\/diet-opt.html"},{"key":"CIT0023","unstructured":"European Medicines Agency (EMA). Waylivra (volanesorsen): an overview of Waylivra and why it is authorised in the EU. Amsterdam, The Netherlands; 2019 [cited 2020 Mar 15]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/waylivra-epar-medicine-overview_en.pdf"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M066399"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1715944"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2015.26"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.3122\/jabfm.19.3.310"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1097\/01.mcg.0000436438.60145.5a"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/807434"},{"key":"CIT0030","first-page":"384719","volume":"2012","author":"Chen Y-H","year":"2012","journal-title":"Case Rep Pediatr"},{"issue":"2","key":"CIT0031","first-page":"92","volume":"1","author":"Patil M","year":"2011","journal-title":"Case Study Rep"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2007.00415.x"},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.1080\/14779072.2017.1372193"},{"key":"CIT0034","unstructured":"Rare disease report, familial chylomicronemia syndrome \u2013 understanding FCS. Silver Spring, MD: FDA; 2017."},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.1038\/ncpgasthep0293"},{"key":"CIT0036","unstructured":"Schorn S, Ceyhan GI, Tieftrunk E, et al. Pain management in acute pancreatitis. Pancreapedia. Version 1.0. American Pancreatic Association; May 30, 2015. p. 1\u201313."},{"issue":"5","key":"CIT0037","first-page":"447","volume":"7","author":"Symersky T","year":"2006","journal-title":"JOP"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2013.218"},{"key":"CIT0039","volume-title":"Measuring and Valuing Health Benefits for Economic Evaluation","year":"2017"},{"key":"CIT0040","first-page":"788","volume-title":"The Oxford handbook of health economics","author":"Rowen D","year":"2011"},{"key":"CIT0041","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2010.03136.x"},{"key":"CIT0042","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-1-54"},{"key":"CIT0043","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-1050(199603)5:2<141::AID-HEC189>3.0.CO;2-N"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2020.1776719","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T12:39:21Z","timestamp":1598963961000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2020.1776719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,1]]},"references-count":43,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9,1]]}},"alternative-id":["10.1080\/13696998.2020.1776719"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2020.1776719","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,1]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-02-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-30","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}